Dr Santiago Ponce-Aix – SCLC Post Progression Therapy Options

These videos are intended for healthcare professionals for informative purposes only. Click on the video above to watch Dr Santiago Ponce-Aix outline SCLC post-progression therapy options.

 

 

SCLC Webinar Chapters

 

Introduction for Dr Ponce-Aix

New Standard of Care for ES-SCLC

Retreatment with Platinum as 2^nd line (>90 days)

Immunotherapy in 2^nd line

Biomarker Selection

Lurbinectedin Basket Trial Data

ATLANTIS Trial

RESILIENT Trial

Lurbinectedin plus Irinotecan

Lurbinectedin plus Atezolizumab

Summary

 

ZEPZELCA^® is a registered trademark of PharmaMar SA. ZEPZELCA^® is under license from PharmaMar SA.